Search Results

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director.

Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.

Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application (“sNDA”) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA).

Dizal announced new findings from a biomarker study in non-small cell lung cancer patients with exon 20 insertion mutations, highlighting sunvozertinib as an effective treatment for this patient population.

The highly anticipated results come as the company makes significant changes to its C-suite. Despite the turnover, Dyne said it is looking toward expedited approval pathways for its DMD treatment.

Dizal (SSE:688192) announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.

Dizal presented the latest data from the inaugural global pivotal study WU-KONG1 Part B of sunvozertinib in relapsed or refractory non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations at the 2024 American Society of Clinical Oncology Annual Meeting.